Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Johnson & Johnson's stock rose 2.4% in premarket trading, enough to pace the Dow Jones Industrial Average's DJIA early gainers. Shares of rival Pfizer Inc. (PFE) were up 0.3% in premarket trades and ...

U.S. Bancorp notched a rise in earnings for the latest quarter as it benefited from a lower loan-loss provision and growth in fee income. The healthcare-products maker trimmed and narrowed its ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Accenture downgraded to neutral amid soft bookings, weak guidance, and demand uncertainty. See here to know more on ACN stock ...

Johnson & Johnson shares jumped to their highest price in more than three months as the US-based healthcare group shrugged ...

A retirement-ready portfolio consists of reliable, income-generating stocks that quietly compound over time. Realty Income (O ...

Pfizer (PFE), a global pharmaceutical giant that was once a pandemic darling, is now facing turbulence. Following a period of extraordinary vaccine-driven revenue, the company now faces a more ...

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday.

Analysts expect Domino's Pizza to report an earnings per share (EPS) of $3.94. Anticipation surrounds Domino's Pizza's announcement, with investors hoping to hear about both surpassing estimates and ...

US stocks start up on earnings reports and before a consumer sentiment survey that'll show if consumers are feeling the ...

The pharmaceutical company posted higher earnings and sales for the second quarter, and said longtime financial chief Harry ...